Oslo, Norway, 26 May 2016: Photocure ASA announces today that its Chief Operating Officer, Kathleen Deardorff, has resigned effective 1 June 2016 to pursue other career opportunities. Ms Deardorff has been with Photocure since 2011, serving as Chief Operating Officer during her entire tenure.
"During her five years at Photocure, Kathleen has made significant contributions to the company. She has been an important part of our management team and we wish her all the best in her future endeavours," says Kjetil Hestdal, M.D., Ph.D., President and CEO, Photocure ASA.
During the transition process and search for a suitable full-time successor is successfully fulfilled, Photocure will allocate the position's key operational duties to the current management team.
For further information, please contact:
Photocure
President & CEO Kjetil Hestdal
Tel: + 47 913 19 535
Email: kh@photocure.no
CFO Erik Dahl
Tel: +47 450 55 000
E-mail: ed@photocure.no
Notes to editors
About Photocure ASA
Photocure, headquartered in Oslo Norway, is a specialty pharmaceutical company and world leader in photodynamic technology. Based on our unique proprietary Photocure Technology(TM) platform, Photocure develops and commercializes highly selective and effective solutions within disease areas with high unmet medical need, such as bladder cancer, HPV and precancerous cervical lesions, colorectal cancer and skin conditions. Our aim is to provide solutions which can improve health outcomes for patients worldwide. Photocure is listed on the Oslo Stock Exchange (OSE: PHO). Information about Photocure is available at www.photocure.com